SMOFLIPID 20% 6 % — DIN 02396963
MEDIUM CHAIN TRIGLYCERIDES (MCT) : 6 % OLIVE OIL : 5 % FISH OIL : 3 % SOYBEAN OIL : 6 % · FRESENIUS KABI CANADA LTD · EMULSION · wholesale supply in Canada
Health Canada status: MARKETED
What is SMOFLIPID 20%?
SMOFLIPID 20% 6 % contains MEDIUM CHAIN TRIGLYCERIDES (MCT) : 6 % OLIVE OIL : 5 % FISH OIL : 3 % SOYBEAN OIL : 6 %. It is listed in the Health Canada Drug Product Database under DIN 02396963, held by FRESENIUS KABI CANADA LTD, supplied as EMULSION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 09-Feb-2016. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is SMOFLIPID 20% used for?
Supply of energy, essential fatty acids, and omega-3 fatty acids to adults as part of parenteral nutrition when oral/enteral nutrition is impossible, insufficient, or contraindicated.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Fat Emulsions in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
4 holders have a Canadian DIN containing Fat Emulsions, across 13 DINs, of which 3 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| FRESENIUS KABI CANADA LTD | 4 | 2 | INTRALIPID 10%, INTRALIPID 20%, INTRALIPID 30%, SMOFLIPID 20% | Sourceable in Canada |
| BAXTER CORPORATION | 1 | 1 | CLINOLEIC 20% | Sourceable in Canada |
| HOSPIRA HEALTHCARE ULC | 5 | 0 | LIPOSYN II 10%, LIPOSYN II 20%, LIPOSYN II INJ 10%, LIPOSYN III 10%, LIPOSYN III 20% | No marketed DIN |
| BAXTER CORPORATION CLINTEC NUTRITION DIVISION | 3 | 0 | 10% TRAVAMULSION LIQ IV, 20% TRAVAMULSION LIQ IV, COLIP 20% | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 6 % |
|---|---|
| Dosage form | EMULSION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | 100 mL (box of 10), 250 mL (box of 10), 500 mL (box of 12), 1000 mL (box of 6). Multilayered plastic bag with oxygen barrier overpouch and oxygen absorber. |
| Storage | Store at 15-25°C. Do not freeze. (Note: General storage section 11 not fully provided in text, but standard for this product class). |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Fat Emulsions |
|---|---|
| ATC code | B05BA02 |
| AHFS class | 40:20.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02396963 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2396963 |
| Brand name | SMOFLIPID 20% |
| Generic / active ingredient | MEDIUM CHAIN TRIGLYCERIDES (MCT) : 6 % OLIVE OIL : 5 % FISH OIL : 3 % SOYBEAN OIL : 6 % |
| Market authorization holder | FRESENIUS KABI CANADA LTD |
| Health Canada schedule | Ethical |
| ATC code | B05BA02 |
| ATC anatomical main group | B — Blood and blood-forming organs |
| ATC therapeutic subgroup | B05BA |
| Current status | MARKETED |
| Status date | 09-Feb-2016 |
| Original market date | 2013-05-08 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Standard dose: 1-2 g lipid/kg/day (5-10 mL/kg/day). Max infusion rate: 0.15 g lipid/kg/hour. Administer via peripheral or central vein over 12-24 hours.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to fish, egg, soybean, peanut; severe hyperlipidemia, liver/renal insufficiency (without dialysis), blood coagulation disorders, acute shock, unstable metabolic conditions.
Warnings and precautions
Monitor triglyceride levels; risk of fat overload syndrome. Risk of allergic reactions (soy, fish, egg). Monitor glucose, liver function, and electrolytes. Risk of metabolic acidosis.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
3 of 13 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| CLINOLEIC 20% | 16 % | EMULSION | BAXTER CORPORATION | MARKETED | 02344327 |
| INTRALIPID 20% | 20 % | EMULSION | FRESENIUS KABI CANADA LTD | MARKETED | 02065673 |
| 10% TRAVAMULSION LIQ IV | 1.2 G / 100 ML | LIQUID | BAXTER CORPORATION CLINTEC NUTRITION DIVISION | CANCELLED POST MARKET | 02016028 |
| 20% TRAVAMULSION LIQ IV | 20 G / 100 ML | LIQUID | BAXTER CORPORATION CLINTEC NUTRITION DIVISION | CANCELLED POST MARKET | 02016036 |
| COLIP 20% | 15 G / 100 ML | EMULSION | BAXTER CORPORATION CLINTEC NUTRITION DIVISION | CANCELLED POST MARKET | 02230772 |
| INTRALIPID 10% | 10 % | EMULSION | FRESENIUS KABI CANADA LTD | DORMANT | 02065681 |
| INTRALIPID 30% | 30 % | EMULSION | FRESENIUS KABI CANADA LTD | DORMANT | 02216175 |
| LIPOSYN II 10% | 5 % | EMULSION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | 00720976 |
| LIPOSYN II 20% | 10 % | EMULSION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | 00720968 |
| LIPOSYN II INJ 10% | 700 MG / 100 ML | EMULSION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | 00818712 |
2 · Same class — other molecules in ATC B05BA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Combinations | 2.5% TRAVASOL AMINO ACID INJECTION WITH ELECTROLYTES IN 10% DEXTROSE · 2.5% TRAVASOL AMINO ACID INJECTION WITH ELECTROLYTES IN 10% DEXTROSE CLINIMIX · 2.5% TRAVASOL AMINO ACID INJECTION WITHOUT ELECTROLYTES IN 10% DEXTROSE QUICKMIX · 2.5%TRAVASOL AMINO ACID INJ.W.ELEC.W.25%DEX · +51 more | 79 | 22 | Yes |
| Carbohydrates | 10% DEXTROSE INJECTION USP · 10% DEXTROSE INJECTION, USP · 13.3% DEXTROSE INJECTION, USP · 20% DEXTROSE INJECTION USP · +18 more | 32 | 9 | Yes |
| Amino Acids | 20% PROSOL · 4.25% AMINO ACID INJECTION WITHOUT ELECTROLYTES IN 20% DEXTROSE QUICKMIX · 8.5% FREAMINE III · AMINOSYN · +20 more | 26 | 4 | Yes |
| Fat Emulsions | 10% TRAVAMULSION LIQ IV · 20% TRAVAMULSION LIQ IV · CLINOLEIC 20% · COLIP 20% · +9 more | 13 | 3 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC B05B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| B05BB | Electrolytes · Electrolytes With Carbohydrates | 90 | 27 |
| B05BC | Carbamide · Carbamide, Combinations · Mannitol | 11 | 5 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.